Literature DB >> 7116690

Kinetics of interaction of immune complexes with complement receptors on human blood cells: modification of complexes during interaction with red cells.

M E Medof, G M Prince, J J Oger.   

Abstract

Antigen-antibody complexes, composed of 125I-BSA and guinea-pig or rabbit antibody, were incubated at 37 degrees C with human blood cells suspended in autologous serum and kinetics of binding analysed. When purified polymorphonuclear (PMN) or mononuclear cells (MNC) were studied, maximum binding was observed within 8 min, and immune complexes (IC) remained associated with cells even after 1 hr. When cells were studied unseparated (in the same amount of serum), maximum binding was observed slightly earlier (within 4 min), but within 15 min most of the IC were found in the serum. Separation of cell types at the time of maximal binding and studies with cell preparations depleted of different elements revealed that binding was principally to red blood cells (RBC). IC recovered in the serum 16 min after addition to unseparated cells bound very slowly to purified PMN or MNC; binding after 30 min was 10-15% of that observed with fresh IC at 8 min. Ultracentrifugal analysis revealed that reduction in binding efficiency correlated with decrease in the size of IC. RBC isolated after binding and release of IC bound newly-formed IC was identical rapidity and capacity as fresh RBC, indicating that receptors were not altered by IC. Kinetics studies with serum in the absence of cells suggested that interaction with RBC accelerated the rate of change in binding properties of IC. Rates of binding and release were independent of antigen/antibody ratio but were slowed and binding to RBC sustained when diluted or hypocomplementaemic (SLE) serum was substituted for neat serum. Our results suggest that competition for IC by RBC is associated with loss of ability of IC to bind to other blood cell types and reduction in size of IC, and that abnormalities of complement can lead to prolonged association of IC with RBC.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7116690      PMCID: PMC1536626     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque.

Authors:  D English; B R Andersen
Journal:  J Immunol Methods       Date:  1974-08       Impact factor: 2.303

Review 2.  The complement system of man. I.

Authors:  S Ruddy; I Gigli; K F Austen
Journal:  N Engl J Med       Date:  1972-09-07       Impact factor: 91.245

Review 3.  The effects of immune complexes on blood platelets and their relationship to complement activation.

Authors:  S L Pfueller; E F Lüscher
Journal:  Immunochemistry       Date:  1972-11

4.  Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G.

Authors:  H Huber; M J Polley; W D Linscott; H H Fudenberg; H J Müller-Eberhard
Journal:  Science       Date:  1968-12-13       Impact factor: 47.728

5.  Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3.

Authors:  I Gigli; R A Nelson
Journal:  Exp Cell Res       Date:  1968-07       Impact factor: 3.905

6.  C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

7.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

8.  Human lymphocytes bear membrane receptors for C3b and C3d.

Authors:  A Eden; G W Miller; V Nussenzweig
Journal:  J Clin Invest       Date:  1973-12       Impact factor: 14.808

9.  Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b.

Authors:  G D Ross; M J Polley; E M Rabellino; H M Grey
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

10.  Receptor for soluble C3 and C3b on human lymphoblastoid (RAJI) cells. Properties and biologocal significance.

Authors:  A N Theofilopoulos; V A Bokisch; F J Dixon
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

View more
  16 in total

1.  In vivo binding of circulating immune complexes by C3b receptors (CR1) of transfused erythrocytes.

Authors:  Y Inada; M Kamiyama; T Kanemitsu; H Ikegami; K Watanabe; W S Clark; Y Asai
Journal:  Ann Rheum Dis       Date:  1989-04       Impact factor: 19.103

2.  Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions.

Authors:  Y C Ng; J A Schifferli; M J Walport
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

Review 3.  CR1 and the cell membrane proteins that bind C3 and C4. A basic and clinical review.

Authors:  J G Wilson; N A Andriopoulos; D T Fearon
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

4.  A lysine-binding protein in SLE sera inhibits the binding of immune complexes to normal erythrocyte CR1 (complement receptor type 1).

Authors:  Y C Ng; D K Peters; S A Cederholm-Williams; M J Walport
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

5.  Normal C3b receptor (CR1) genomic polymorphism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon?

Authors:  P E Ruuska; I Ikäheimo; S Silvennoinen-Kassinen; M L Käär; A Tiilikainen
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

6.  Mechanism of transfer of immune complexes from red blood cell CR1 to monocytes.

Authors:  W Emlen; V Carl; G Burdick
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

7.  Alternative pathway-mediated rebinding of immune complexes to human red blood cells.

Authors:  M E Medof; G M Prince
Journal:  Immunology       Date:  1983-09       Impact factor: 7.397

8.  C3b receptor (CR1) genomic polymorphism in rheumatoid arthritis. Low receptor levels on erythrocytes are an acquired phenomenon.

Authors:  A Kumar; A N Malaviya; S Sinha; P S Khandekar; K Banerjee; L M Srivastava
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

9.  Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

10.  In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees.

Authors:  R P Kimberly; J C Edberg; L T Merriam; S B Clarkson; J C Unkeless; R P Taylor
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.